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Background: Mounting evidences have showed the important role of transforming growth factor-β (TGF-β) in
immunological surveillance of tumors. Some studies have also indicated human leukocyte antigen (HLA)-G-associated
immune escape involving TGF-β management in gastric cancer (GC). However, the mechanism underlying it is
unclear. This study aims to verify the correlations between HLA-G and TGF-β, involving the potential targeting of
miR-152 on HLA-G.
Results: TGF-β and HLA-G levels were analyzed in blood samples from twenty GC patients with ELISA assays,
while TGF-β showed directly proportional to HLA-G levels in GC patients, and TGF-β induced HLA-G up-regulation
was also confirmed in GC cell lines. Furthermore, miR-152 expression could be inhibited by TGF-β, and the
negative post-transcriptionally regulation of miR-152 on HLA-G was also demonstrated through gain- and
loss-of-function studies. Besides, miR-152 overexpression repressed HLA-G up-regulation induced by TGF-β.
And, miR-152 expression levels showed inversely proportional to both HLA-G and also TGF-β levels in GC
patients.
Conclusion: TGF-β could induce HLA-G expression in GC by inhibiting miR-152, involving its negative
regulation on HLA-G. Since TGF-β induced HLA-G up-regulation plays important role in immune escape, a
potential application of miR-152 was suggested in GC treatment, or miR-152 might be one potential
biomarker for GC.
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Gastric cancer (GC) is the most frequent cause of cancer-
related death, with an incidence of approximately 934,000
cases per year in East Asia [1]. Despite significant ad-
vances in diagnostic and therapeutic approaches during
the last decades, the prognosis of GC also remains dismal
because of its high recurrence and metastasis [2]. The
pathogenesis of GC is multifactorial, and genetic alter-
ations involving tumor suppressor genes, oncogenes,
growth factors, and cell adhesion molecules are associated
with the predisposition to GC [3]. Therefore, gaining a
better understanding of the molecular mechanisms in-
volved in GC is of great clinical significance.* Correspondence: fengjliuj@163.com
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article, unless otherwise stated.MicroRNAs (miRNAs) are endogenously expressed
noncoding RNAs that post-transcriptionally regulate
expression of their target genes [4]. Increasing numbers
of studies have shown aberrant expression of miRNAs
presented in different types of cancers and have shown
that miRNAs were involved in the regulation of the
proliferation, differentiation, and apoptosis [5]. In GC,
many miRNAs have been found to suppress metastasis,
as well as help in the prediction of metastasis through
their expression levels [6]. MiR-152 has been identified
as a down-regulated miRNA in GC [7], and a recent
study has revealed that miR-152 could suppress gastric
cancer cell proliferation and motility by targeting
CD151, which is an essential marker for the prognosis
of GC due to the positive association with the invasive-
ness of GC [8]. However, the detailed role of miR-152
is still unclear.is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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T cells has been demonstrated as an important factor
for suppressing antitumor immune responses, while in-
creased TGF-β level has been reported in gastric cancer
[9, 10]. Furthermore, TGF-β is reported to be critical
for tumor progression and evasion from immune sur-
veillance [11]. Although the mechanism of TGF-β in
immune evasion is unclear, some studies have indicated
that Human leukocyte antigen (HLA)-G is involved in
it. Increased HLA-G level has been also reported in GC
patients [12], and HLA-G-positive gastric cancers are
often associated with poor survival [13]. Moreover,
HLA-G associated immune escape in gastric cancer
might be mediated by suppressing CD8+ T lympho-
cytes and increasing local Foxp3+ regulatory T (Treg)
cells [14].
In silico analysis of microRNAs targeting the HLA-G
3'-UTR alleles and haplotypes has been performed with
results indicating miR-152 targeting on HLA-G [15]. Be-
sides, the relationship between miR-152 and HLA-G has
also been investigated in human trophoblast cell line,
which revealed that miR-152 could repress HLA-G ex-
pression and overexpression of miR-152 led to increased
NK cell–mediated cytolysis, indicate that miR-152 may
function as an immune system enhancer [16]. However,
the modulation of miR-152 on HLA-G expression has
not been proven yet in GC, let along relative mecha-
nisms underlying TGF-β-induced immune escape. Our
study found that HLA-G level is positively associated
with TGF-β in GC patients. Therefore, we want to inves-
tigate whether HLA-G level was regulated by miR-152
expression in GC cells. Additionally, the regulated role
of miR-152 was further confirmed in TGF-β-induced
immune escape, as well as miR-152 expression in GC
patients.Methods
Patients and specimens
Paraffin-embedded, formalin-fixed tumor sections
were obtained from twenty patients (15 males, 5
females) with gastric cancer that underwent surgical
resection from September 2012 to July 2013 at the
Qilu Hospital of Shandong University. Peripheral
blood samples were collected from these patients one
day before surgery. And, EDTA-plasma were prepared
as described before [17] and frozen at -80 °C immedi-
ately for future use. None of the patients had received
immunosuppressive drugs or chemotherapy before
surgical resection. The study was approved by the
Research Ethics Committee of Qilu Hospital of
Shandong University, and written informed consents
were obtained from these patients before participating
in the study.Cell culture and treatment
Two human GC cell lines, BGC823 and SGC7901, were
obtained from the Chinese Academy of Sciences (Shanghai,
China). Cells were cultured in RMPI-1640 medium
supplemented with 10 % FBS (Invitrogen, NY, USA) and
antibiotics (1 % streptomycin/penicillin, Sigma-Aldrich) at
37 °C with 5 % CO2. After approximately 80 % confluence,
the cells were starved for 24 h and treated without or with
recombinant human TGF-β (R&D Systems, Minneapolis,
MN) at various doses and for various durations according
to the requirements.
ELISA assays
EDTA-plasma samples or cell culture supernatants after
48 h incubation in serum-free medium were prepared for
ELISA (Enzyme-Linked Immuno Sorbent Assays) analysis.
TGF-β levels and soluble HLA-G concentrations were
measured by use of a TGF-β ELISA kit (R&D Systems,
Minneapolis, MN) and sHLA-G kit (Biovendor&Exbio,
Praha, CZ) respectively according to the manufacturer’s
instructions. Three independent experiments were re-
peated for each point.
Transfection and luciferase assay
Double-stranded miR-152 mimics, single-stranded
miR-152 inhibitor, or their relative negative control
RNA (GenePharma, Shanghai, China) at a final con-
centration of 50 nM was introduced into cells. And,
cells were transfected at approximately 70 % confluence
using Lipofectamine 2000 (Invitrogen) in Opti-MEM
medium (Invitrogen). PGL3-HLA-G was generated using
the following primers for the amplification of HLA-G
3’UTR HLA-G-(3’UTR)-forward: 5’-ACTCTCATCGAGG
GAGGAAA-3’; HLA-G-(3’UTR)-reverse: 5’-AAAGTTCT
CATGTCTTCCATTT-3’. The PCR fragment was cloned
into a firefly luciferase vector (pGL3; Promega, Madison,
WI) within KpnI and XhoI restriction sites (Invitrogen).
Mutation in the miR-152 binding-sites module of HLA-G
3’UTR was introduced by site-directed mutagenesis for
the construction of Mut-HLA-G luciferase plasmid
(PGL3-mut-HLA-G). Then, pGL3-HLA-G and PRL-TK
Renilla luciferase plasmid were co-transfected, together
with miR-152 mimics, inhibitor or negative miRNA
(GenePharma) for luciferase reporter assay. After 24 h
incubation, luciferase activity was measured using the
Dual Luciferase Reporter 1000 Assay System (Promega),
with results normalized to those of Renilla luciferase activ-
ities. All experiments were carried out at least in triplicate.
RNA isolation and quantitative real-time PCR
Total RNA was isolated from cells and tissues using Trizol
(Invitrogen). For the detection of the HLA-G mRNA,
RNA was reverse transcribed into cDNA primed by oligo-
dT primers using SuperScript III Reverse Transcriptase
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GAPDH was used as an endogenous control. For the de-
tection of mature miR-152, the enrichment of small RNA
was carried out with the mirVana miRNA Isolation Kit
(Ambion, Austin, TX). Small nuclear RNA U6 was used as
an endogenous control. Quantitative real-time PCR
(qRT-PCR) was performed on ABI 7300 SYBR Premix
Ex Taq from Takara (Tokyo, Japan). Specific primers for




reverse: 5’-CTGTGGTCATGAGTCCTTCC-3’. Primers for
miR-152 and U6 were purchased from GeneCopoeia
(Rockville, MD, USA). Data analysis was done by the ΔCT
method for relative quantification.Statistical analysis
The results are presented as mean ± SD. Correlations
were evaluated by Pearson’s correlation. Differences be-
tween groups were analyzed using a one-way ANOVA,
Mann-Whitney U test or χ2 test, where appropriate.
Statistical analyses were performed using SPSS 17.0
computer software (SPSS Inc., Chicago, IL). P < 0.05 was
considered statistically significant.Results
Clinical and demographic characteristics
Retrospective examination was performed of twenty GC
patients who underwent surgery for gastric cancer from
2012 to 2013 at the Qilu Hospital of Shandong University.
Patient characteristics are shown in Table 1.Table 1 Characteristic of patients
Variable Patients
Number of cases 20
Sex
Male/Female 15/5











Poor 16TGF-β promoted the expression of HLA-G in GC
To elucidate the relationship between the levels of TGF-β
and HLA-G in GC, their concentrations were analyzed in
the peripheral blood samples from GC patients. A strong
positive correlation between TGF-β and HLA-G levels
evaluated by Pearson’s regression (R2 = 0.5455; p < 0.001)
was noted in Fig. 1a. In order to investigate the relation-
ship between TGF-β and HLA-G, two human GC cell
lines, BGC823 and SGC7901, were co-incubated with
TGF-β at various doses (2.5, 5 or 10 ng/ml). Then, the
mRNA expression and supernatant level of HLA-G were
detected after treated for 24 h and 48 h respectively. As
shown in Fig. 1b and c, HLA-G level was significantly up-
regulated under TGF-β treatment in a dosage dependent
manner. Over 2.5-fold increase of HLA-G mRNA level
was observed in both BGC823 and SGC7901 cells when
treated with 10 ng/ml TGF-β (Fig. 1b), while soluble
HLA-G concentration increased from approximately
10 ng/ml to 21 ng/ml or 12 ng/ml to 26 ng/ml in BGC823
and SGC7901 cell cultures respectively (Fig. 1c).
MiR-152 expression was negatively regulated by TGF-β
addition in GC cell lines
As a first step to reveal the functional role of miR-152,
involving targeting on HLA-G, miR-152 expression was
also investigated under TGF-β treatment at various
doses (2.5, 5 or 10 ng/ml) and also for various durations
(6, 12 or 24 h). As expected, miR-152 expression was
significantly suppressed by TGF-β in both dosage and
time dependent manner. Around 0.3-fold change of
miR-152 expression was detected when treated with
10 ng/ml TGF-β for 12 h (Fig. 2a) or 5 ng/ml TGF-β for
24 h (Fig. 2b). Since increased HLA-G level was also ob-
served under TGF-β treatment, it can be speculated that
the potential targeting of miR-152 on HLA-G involved
in TGF-β-induced up-regulation of HLA-G.
MiR-152 showed negative targeting on HLA-G expression
in GC cell lines
In order to verify aforementioned speculation, the po-
tential targeting of miR-152 on HLA-G was thoroughly
investigated. Firstly, the binding sites of miR-152 on
HLA-G 3’UTR was analyzed through sequence analysis,
with derived Mut-HLA-G 3’UTR (Fig. 3a). The expres-
sion of miR-152 was confirmed after miR-152 mimics or
inhibitor transfection for 12 h in both BGC823 and
SGC7901 cells (Fig. 3b). After transfection for 24 h,
HLA-G mRNA level showed significantly decrease or
increase in miR-152 overexpressing or inhibiting cells,
respectively (Fig. 3c). And, results from luciferase assay
showed that HLA-G 3’UTR was also negatively regulated
by miR-152, while no obvious regulation on Mut-HLA-G
3’UTR was observed at the same time (Fig. 3e and f).
Moreover, similar trends of soluble HLA-G concentration
Fig. 1 Correlation between TGF-β and HLA-G in GC. a. The concentration of TGF-β showed directly proportional to the HLA-G levels from the
peripheral blood of twenty GC patients. R2 = 0.5455; p < 0.001. b. After treated with TGF-β (2.5, 5 or 10 ng/ml) for 24 h, HLA-G mRNA level was
significantly upregulated in a dosage dependent manner in GC cell lines like BGC823 and SGC7901. c. ELISA analysis showed increased HLA-G
level in the same manner after TGF-β treatment for 48 h. *P < 0.05; **P < 0.01
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ing that miR-152 suppressed HLA-G expression post-
transcriptionally in GC cells.
Inhibition of TGF-β on miR-152 expression contributed to
induced HLA-G levels
Further experiments were performed to investigate
whether overexpression of miR-152 could attenuate the
up-regulation of HLA-G induced by TGF-β. After
transfected with miR-152 mimics for 12 h, BGC823 and
SGC7901 cells were prepared for the treatment withoutFig. 2 TGF-β inhibited miR-152 levels in GC cell line. The expression of miR-
(2.5, 5 or 10 ng/ml for 12 h; a) and time (5 ng/ml for 6, 10 or 24 h; b) dependor with TGF-β (5 ng/ml). As expected, TGF-β induced
increase of HLA-G mRNA level was attenuated by
miR-152 overexpression (Fig. 4a), as well as soluble
HLA-G concentration (Fig. 4b). On the other hand,
miR-152 expression was also detected in GC patients’
tissues. And, miR-152 expression levels showed in-
versely proportional to both HLA-G concentration
(Fig. 4c) and also TGF-β levels (Fig. 4d). Taken to-
gether, it was concluded that TGF-β induced HLA-G
expression by inhibiting miR-152, involving its negative
regulation on HLA-G.152 was downregulated under TGF-β treatment in dosage
ent manner. *P < 0.05; **P < 0.01
Fig. 3 MiR-152 regulated HLA-G expressions in BGC823 and SGC7901 cells. a. The binding sites of miR-152 on the wild-type or mutated 3’UTR
sequences of HLA-G, wherein “CTG” and “ACT” were mutated to “AAA” and “GGA” respectively in Mut-HLA-G. b. The expression change of
miR-152 in BGC823 and SGC7901 cells after transfected with miR-152 mimic or inhibitor for 12 h. c. HLA-G mRNA expression in miR-152
overexpressing or inhibiting cells after transfection for 24 h. d. Primers used for the construction of HLA-G luciferase reporter (PGL3-HLA-G)
within HLA-G 3'-UTR sequences. Mutation sites within Mut-HLA-G sequences were indicated with rectangle boxes. e. HLA-G 3’-UTR activity change
resulted from miR-152 dysregulation through luciferase assay. The results were normalized to those of Renilla luciferase activities, and statistically
analyzed as compared to that from the cotransfection with negative miRNA. f. Detection for Mut-HLA-G 3’-UTR activity change. g. HLA-G level
detection after miR-152 mimics or inhibitor transfection for 48 h. *P < 0.05; **P < 0.01
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The TGF-β signalling pathway often plays a critical and
dual role in the progression of human cancer [18]. Dur-
ing the early phase of tumor progression, TGF-β acts as
a tumor suppressor, exemplified by deletions or muta-
tions in the core components of the TGF-β signalling
pathway. On the contrary, TGF-β also promotes pro-
cesses that support tumor progression such as tumorcell invasion, dissemination, and immune evasion. Re-
searchers have demonstrated that TGF-β is required for
the induction and maintenance of regulatory T cells
(Tregs) [19, 20], while Treg-mediated immunosuppres-
sion represents one of the crucial tumor immune eva-
sion mechanisms in tumor progression [21]. Moreover,
TGF-β and Tregs showed a positive correlation in circu-
lation of GC patients, suggesting that TGF-β may
Fig. 4 TGF-beta induced HLA-G expression by inhibiting miR-152. BGC823 and SGC7901 cells were transfected with miR-152 mimics for 12 h, then
incubated for 12 h (for qPCR analysis) or 24 h (for ELISA analysis) and finally treated with TGF-β (5 ng/ml). TGF-β induced increase of mRNA level
(a) or concentration (b) of HLA-G was attenuated by miR-152 overexpression. *P < 0.05; **P < 0.01. c. The expression of miR-152 in GC tissues was
inversely proportional to the HLA-G levels of GC patients. R2 = 0.5267; p < 0.001. D. MiR-152 expression levels also showed inversely proportional
to the concentration of TGF-β. R2 = 0.5944; p < 0.001
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fore, TGF-β might act as an important factor for sup-
pressing antitumor immune responses in GC
progression.
HLA-G, a non-classic MHC class I protein, was first
observed on extravillous cytotrophoblasts that play an
important role in immune tolerance during pregnancy
[23]. Studies have shown that HLA-G is detected in
tumor tissue but rarely in normal tissue, suggesting its
specific association with tumor growth and progression,
for example by suppressing immune regulation, similar
to maternal immune tolerance [24]. Many studies have
reported the association between HLA-G-positive gastric
cancer patient and poor survival [13], with a recent
study suggesting the tumor escape mechanism by in-
creasing Foxp3 + Treg lymphocytes and decreasing CD8
+ T lymphocytes in GC [14]. HLA-G expression is also
thought to contribute to the escape in immune surveil-
lance by suppressing NK cell function [25], while TGF-β
can also repress NK cell activity [18]. In the present
study, we found a strong positive correlation betweenTGF-β and HLA-G in circulation of GC patients, while
TGF-β induced HLA-G up-regulation was also demon-
strated in GC cell lines.
Results from an in silico analysis of microRNAs target-
ing the HLA-G 3'-UTR suggest that some miRNAs might
play a relevant role on the HLA-G expression pattern, in-
cluding miR-152 [15]. MiR-152 belongs to miR-148/152
family that consists of miR-148a, miR-148b, and miR-152.
Many studies have indicated that miR-152 potentially
functions as a tumor suppressor and is down-regulated in
various tumor types [26–28]. In GC, it was noted that
both miR-148a and miR-152 were down-regulated in can-
cer tissue and cell lines, involving the cholecystokinin B
receptor (CCKBR) protein [7]. In this study, we validated
that HLA-G expression was repressed by miR-152 while
miR-152 expression was also inhibited by TGF-β induc-
tion in GC cell lines. These results suggest that miR-152
might also play an essential role in GC immune escape.
Further experiments showed that miR-152 overexpression
could reversely repress TGF-β induced HLA-G up-
regulation. Moreover, miR-152 expression level in GC
Guan et al. Journal of Biomedical Science  (2015) 22:107 Page 7 of 7tissues also showed strong negatively proportional to
both TGF-β and HLA-G levels in circulation. Our work
sheds new light on the regulation of GC progression by
miR-152, involving HLA-G-associated immune escape
regulated by TGF-β.
Conclusions
In summary, this is the first study to show the positive
correlation between TGF-β and HLA-G in circulation of
GC patients, and we also found that miR-152 expression
played a regulatory role in TGF-β induced HLA-G up-
regulation. Further study could be executed to investi-
gate the potential application of miR-152 in GC
treatment.
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